Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001734424-26-000003
Filing Date
2026-03-04
Accepted
2026-03-04 16:30:46
Documents
1
Period of Report
2026-03-02

Document Format Files

Seq Description Document Type Size
1 form4-03042026_040342.html 4  
1 form4-03042026_040342.xml 4 3902
  Complete submission text file 0001734424-26-000003.txt   5379
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650) 822-5500
Annexon, Inc. (Issuer) CIK: 0001528115 (see all company filings)

EIN.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O ANNEXON, INC. 1400 SIERRA POINT PARKWAY, BLDG C, 200 BRISBANE CA 94005
Business Address
Dananberg Jamie (Reporting) CIK: 0001734424 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39402 | Film No.: 26721878